GenSight Biologics’ Gene Therapy Candidate May Help Vision Loss in LHON Patients – Mitochondrial Disease News
Mitochondrial Disease News |
GenSight Biologics' Gene Therapy Candidate May Help Vision Loss in LHON Patients
Mitochondrial Disease News A presentation of the data, “Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber's Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation,” is set for April 25 at the 2017 annual meeting of the … |
